Evidence map›Paper›PMID 39506020›Full record

ArticleScientific reports2024

Local effects of non-pharmaceutical interventions on mitigation of COVID-19 spread through decreased human mobilities in Japan: a prefecture-level mediation analysis.

Shohei Nagata, Yuta Takahashi, Hiroki M Adachi, Glen D Johnson, Tomoki Nakaya

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shohei NagataCo-creation Center for Disaster Resilience, International Research Institute of Disaster Science, Tohoku University, 468-1 Aoba, Aramaki, Aoba-ku, Sendai, 980-0845, Japan.
Yuta TakahashiGraduate School of Environmental Studies, Tohoku University, 468-1 Aoba, Aramaki, Aoba- ku, Sendai, 980-0845, Japan.
Hiroki M AdachiCo-creation Center for Disaster Resilience, International Research Institute of Disaster Science, Tohoku University, 468-1 Aoba, Aramaki, Aoba-ku, Sendai, 980-0845, Japan.
Glen D JohnsonDepartment of Environmental, Occupational and Geospatial Health Sciences, City University of New York School of Public Health, 55 West 125th Street, New York, NY, 10027, USA.
Tomoki NakayaGraduate School of Environmental Studies, Tohoku University, 468-1 Aoba, Aramaki, Aoba- ku, Sendai, 980-0845, Japan. tomoki.nakaya.c8@tohoku.ac.jp.

Funding

the Ministry of Health, Labour, and Welfare, Japan JPMH21HA2016
6 · The paper itself

Abstract

To control the COVID-19 epidemic, the Japanese government and the local governments have repeatedly implemented non-pharmaceutical interventions (NPIs) throughout 2020-2022. Using Bayesian state-space mediation models, we examined the effect of repeated NPIs on infection spread mitigation, mediated by human mobility changes in each prefecture during three epidemic phases: from April 1, 2020 to February 28, 2021; from March 1, 2021 to December 16, 2021; and from December 17, 2021 to December 31, 2022. In the first phase, controlling downtown populations at nighttime was effective in mitigating the infection spread in almost all prefectures. In the second and third phases, the effect was not clear, especially in metropolitan prefectures. Controlling visitors from the central prefectures of metropolitan areas was effective in mitigating infection spread in the surrounding prefectures during all phases. These results suggest that the local spread of infection can be mitigated by focusing on nighttime human mobility control in downtown areas before the epidemic spreads widely and transmission routes become more diverse, and that the geospatial spread of infection can be prevented by controlling the flows of people from large cities to other areas.

Indexed as

COVID-19Bayes TheoremCitiesCommunicable Disease ControlHumansJapanSARS-CoV-2

Identifiers

PMID39506020
PMCPMC11541980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.